Expression of heparanase, Mdm2, and erbB2 in ovarian cancer

被引:0
|
作者
Ginath, S
Menczer, J
Friedmann, Y
Aingorn, H
Aviv, A
Tajima, K
Dantes, A
Glezerman, M
Vlodavsky, I
Amsterdam, A [1 ]
机构
[1] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
[2] Holon & Sackler Fac Med, Edith Wolfson Med Ctr, Gynecol Oncol Unit, Dept Obstet & Gynecol, Tel Aviv, Israel
[3] Hebrew Univ Jerusalem, Hadassah Hosp, Dept Oncol, IL-91120 Jerusalem, Israel
关键词
heparanase; Mdm2; erbB2; apoptosis; ovarian cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is the most lethal of gynecological malignancies. Yet early diagnosis and prognosis are far from being satisfactory. Degradation of heparan sulfate proteoglycans by heparanase appears to play an important role in the invasiveness of tumor cells through the basement membrane and into the extracellular matrix. Recent cloning of the heparanase gene and generation of monoclonal antibodies against the enzyme permit to examine tumor cell expression of the enzyme. The aim of the present study was to assess heparanase activity and localization in various subtypes of epithelial ovarian cancer in correlation with oncogene expression. Histologically confirmed malignant ovarian tissue from ten women and tissue from 2 benign ovarian tumors and 4 normal ovaries were assessed for heparanase presence, activity and localization, incidence of apoptosis and expression of the oncogenes erbB2 and Mdm2. Heparanase immunohistostaining and activity were present in mucinous carcinomas and were more intense than in endometrioid and in serous carcinomas. The lowest activity was observed in benign ovarian tumors and normal ovaries. In ovarian carcinomas the enzyme was intensely concentrated in the cytoplasm of the cancerous cells. In contrast, in normal ovaries and benign tumors the enzyme was predominantly localized in endothelial cells lining blood capillaries. The rate of apoptosis was considerably higher in mucinous and endometrioid carcinomas, and was lower in serous and primary peritoneal carcinomas. Extremely high concentration of heparanase was often demonstrated in apoptotic cells. Endometrioid and serous carcinomas showed high expression of Mdm2 and erbB2 while mucinous carcinomas showed low expression. In benign ovarian tumors and normal ovaries the expression of both oncoproteins was extremely low. In conclusion ovarian carcinomas demonstrate higher levels of heparanase than benign tumors and normal ovaries suggesting that the enzyme may play an important role in metastatic spread of the cancerous cells. Apoptosis may be a significant part of the mechanism of the enzyme release into the extacellular space. Although heparanase activity seems to play an essential role in tumor progression, expression of oncogenes, such as erbB2 and Mdm2 seems to play the dominant role in the development of ovarian cancer.
引用
收藏
页码:1133 / 1144
页数:12
相关论文
共 50 条
  • [1] Targeting ERBB2 pathway in ovarian cancer
    Kovtun, Irina, V
    Zhang Piyan
    Harris, Faye R.
    Hou, Xiaonan
    Weroha, Saravut J.
    Vasmatzis, George
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [2] Phosphoproteome of signaling by ErbB2 in ovarian cancer cells
    Sidhanth, C.
    Bindhya, S.
    Krishnapriya, S.
    Manasa, P.
    Shabna, A.
    Alifia, J.
    Patole, C.
    Kumar, V
    Garg, M.
    Ganesan, T. S.
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2022, 1870 (04):
  • [3] hMOF induces cisplatin resistance of ovarian cancer by regulating the stability and expression of MDM2
    Mingbo Cai
    Sulong Xu
    Yuxi Jin
    Jingjing Yu
    Shan Dai
    Xiao-Jing Shi
    Ruixia Guo
    Cell Death Discovery, 9
  • [4] hMOF induces cisplatin resistance of ovarian cancer by regulating the stability and expression of MDM2
    Cai, Mingbo
    Xu, Sulong
    Jin, Yuxi
    Yu, Jingjing
    Dai, Shan
    Shi, Xiao-Jing
    Guo, Ruixia
    CELL DEATH DISCOVERY, 2023, 9 (01)
  • [5] MDM2 sensitizes a human ovarian cancer cell line
    Mi, RR
    Ni, H
    GYNECOLOGIC ONCOLOGY, 2003, 90 (02) : 238 - 244
  • [6] MDM2 GENE ALTERATIONS AND MDM2 PROTEIN EXPRESSION IN BREAST CARCINOMAS
    MARCHETTI, A
    BUTTITTA, F
    GIRLANDO, S
    DALLAPALMA, P
    PELLEGRINI, S
    FINA, P
    DOGLIONI, C
    BEVILACQUA, G
    BARBARESCHI, M
    JOURNAL OF PATHOLOGY, 1995, 175 (01): : 31 - 38
  • [7] TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
    J Kupryjańczyk
    R Mądry
    J Plisiecka-Hałasa
    J Bar
    E Kraszewska
    I Ziółkowska
    A Timorek
    J Stelmachów
    J Emerich
    M Jędryka
    A Płużańska
    I Rzepka-Górska
    K Urbański
    J Zieliński
    J Markowska
    British Journal of Cancer, 2004, 91 : 1916 - 1923
  • [8] TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
    Kupryjanczyk, J
    Madry, R
    Plisiecka-Halasa, J
    Bar, J
    Kraszewska, E
    Ziólkowska, I
    Timorek, A
    Stelmachów, J
    Emerich, J
    Jedryka, M
    Pluzanska, A
    Rzepka-Górska, I
    Urbanski, K
    Zielinski, J
    Markowska, J
    BRITISH JOURNAL OF CANCER, 2004, 91 (11) : 1916 - 1923
  • [9] MDM2 in breast cancer
    Masakazu Toi
    Shigehira Saji
    Akio Suzuki
    Yutaka Yamamoto
    Takeshi Tominaga
    Breast Cancer, 1997, 4 (4) : 264 - 268
  • [10] Mdm2 gene amplification in gastric cancer correlation with expression of mdm2 protein and p53 alterations
    Günther, T
    Schneider-Stock, R
    Häckel, C
    Kasper, HU
    Pross, M
    Hackelsberger, A
    Lippert, H
    Roessner, A
    MODERN PATHOLOGY, 2000, 13 (06) : 621 - 626